within Pharmacolibrary.Drugs.ATC.C;

model C04AD03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.2,
    Cl             = 4.8 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,
    adminCount     = 1,
    Vd             = 0.026,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.021666666666666667,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Pentoxifylline is a methylxanthine derivative that improves microcirculation and reduces blood viscosity. It is used clinically to treat peripheral vascular diseases such as intermittent claudication. Pentoxifylline is approved and in current clinical use in many countries for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after single oral dosing.</p><h4>References</h4><ol><li><p>Shailendrakumar, AM, et al., &amp; Lewis, SA (2020). Improved Oral Pharmacokinetics of Pentoxifylline with Palm Oil and Capmul® MCM Containing Self-Nano-Emulsifying Drug Delivery System. <i>AAPS PharmSciTech</i> 21(4) 118–None. DOI:<a href=&quot;https://doi.org/10.1208/s12249-020-01644-w&quot;>10.1208/s12249-020-01644-w</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32318890/&quot;>https://pubmed.ncbi.nlm.nih.gov/32318890</a></p></li><li><p>Liska, DA, et al., &amp; Cole, CA (2006). Pharmacokinetics of pentoxifylline and its 5-hydroxyhexyl metabolite after oral and intravenous administration of pentoxifylline to healthy adult horses. <i>American journal of veterinary research</i> 67(9) 1621–1627. DOI:<a href=&quot;https://doi.org/10.2460/ajvr.67.9.1621&quot;>10.2460/ajvr.67.9.1621</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16948611/&quot;>https://pubmed.ncbi.nlm.nih.gov/16948611</a></p></li><li><p>Rames, A, et al., &amp; Jaillon, P (1990). Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients. <i>Clinical pharmacology and therapeutics</i> 47(3) 354–359. DOI:<a href=&quot;https://doi.org/10.1038/clpt.1990.39&quot;>10.1038/clpt.1990.39</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2178853/&quot;>https://pubmed.ncbi.nlm.nih.gov/2178853</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C04AD03;
